SCHEMBL7385100

SCHEMBL7385100

COC(=O)C(C(=O)c1ccncc1)c1ccc(OC)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
CYP1A2 P05177 2/20 0.53
LMNA P02545 2/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
GAA P10253 2/20 0.47
CYP1A1 P04798 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP1B1 Q16678 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MAPT P10636 2/20 0.43
PAX8 Q06710 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15665536 0.89 CA1 (0.52) SMN1; SMN2CYP1A2LMNAALDH1A1NPC1
SCHEMBL6479736 0.85 LTA4H (0.47) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL3098048 0.84 NPSR1 (0.52) SMN1; SMN2CYP1A2LMNATDP1ALDH1A1
SCHEMBL28776229 0.84 RAB9A (0.55) SMN1; SMN2CYP1A2ALDH1A1NPC1RAB9A
SCHEMBL3094287 0.82 HPGD (0.57) SMN1; SMN2LMNAALDH1A1NPC1RAB9A
SCHEMBL388412 0.82 RAB9A (0.46) SMN1; SMN2CYP1A2CYP2C9CYP2C19GAA
SCHEMBL3100510 0.82 CYP1A1 (0.50) LMNACYP1A1CYP1B1TDP1ALDH1A1
SCHEMBL3093681 0.81 KMT2A (0.49) SMN1; SMN2CYP1A2LMNAGAAALDH1A1
SCHEMBL1042666 0.81 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL9343806 0.80 CYP1A2 (0.57) SMN1; SMN2CYP1A2LMNACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6352994-B2 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS MERCK SHARP & DOHME LIMITED (GB) 2002-03-05 US disclosed
US-20010018438-A1 Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands MERCK SHARP & DOHME LIMITED 2001-08-30 US disclosed
US-6200982-B1 USEFUL IN THERAPY OF DELETERIOUS MENTAL STATES MERCK & DOHME LIMITED (GB) 2001-03-13 US disclosed
EP-0994873-A1 SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABA A?ALPHA 2/3 LIGANDS MERCK SHARP & DOHME LTD. (GB) 2000-04-26 EP disclosed
WO-1998055480-A1 SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABAAALPHA 2/3 LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1998-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018438-A1 Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands GABRB2, GABRB3, GABRB1 SMN1; SMN2 651/4885CYP1A2 528/4885LMNA 2735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.